{"result": "{\n    \"title\": \"Breast Cancer Research Community\",\n    \"summary\": \"The community revolves around researchers involved in breast cancer studies, with Schneeweiss A being a central figure. The researchers have collaborated on multiple studies, including those on neoadjuvant carboplatin, pertuzumab, and trastuzumab.\",\n    \"rating\": 6.5,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for significant advancements in breast cancer treatment and research.\",\n    \"findings\": [\n        {\n            \"summary\": \"Schneeweiss A's central role\",\n            \"explanation\": \"Schneeweiss A is a key researcher in the community, having collaborated on multiple studies and being a co-author of several research papers. [Data: Entities (692), Relationships (590, 591, 585, 588, 587)]\"\n        },\n        {\n            \"summary\": \"Collaborations and research focus\",\n            \"explanation\": \"The researchers in the community have collaborated on multiple studies, focusing on breast cancer treatment and research. This collaboration has led to significant advancements in the field. [Data: Relationships (590, 591, 585, 588, 587)]\"\n        },\n        {\n            \"summary\": \"Research focus on breast cancer treatment\",\n            \"explanation\": \"The researchers in the community have focused on breast cancer treatment, specifically on neoadjuvant carboplatin, pertuzumab, and trastuzumab. This focus has led to significant advancements in the field. [Data: Entities (692, 693, 696, 695, 676, 694, 697), Relationships (590, 591, 585, 588, 587)]\"\n        },\n        {\n            \"summary\": \"Potential for significant advancements\",\n            \"explanation\": \"The research conducted by the community has the potential to lead to significant advancements in breast cancer treatment and research. [Data: Entities (692, 693, 696, 695, 676, 694, 697), Relationships (590, 591, 585, 588, 587)]\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n692,\"\"\"SCHNEEWEISS A\"\"\",\"Here is a comprehensive summary of the data:\n\nSchneeweiss A is a researcher who has been involved in multiple studies on breast cancer. Specifically, they have conducted research on neoadjuvant carboplatin in early breast cancer, as well as the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Additionally, Schneeweiss A has authored research papers on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, and has authored multiple studies on breast cancer in general.\",8\r\n693,\"\"\"CHIA S\"\"\",\"\"\"Chia S is a researcher involved in the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",1\r\n696,\"\"\"ENIU A\"\"\",\"\"\"Eniu A is a researcher involved in the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",1\r\n695,\"\"\"HARVEY V\"\"\",\"\"\"Harvey V is a researcher involved in the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",1\r\n676,\"\"\"HEGG R\"\"\",\"Here is a comprehensive summary of the data:\n\nHegg R is a researcher who has been involved in multiple studies related to breast cancer treatment. Specifically, they have contributed to research on the combination of pertuzumab, trastuzumab, and docetaxel for the treatment of metastatic breast cancer. Additionally, they have studied the combination of pertuzumab and trastuzumab with standard neoadjuvant chemotherapy regimens in patients with HER2-positive early breast cancer.\",1\r\n694,\"\"\"HICKISH T\"\"\",\"\"\"Hickish T is a researcher involved in the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",1\r\n697,\"\"\"WALDRON-LYNCH M\"\"\",\"\"\"Waldron-Lynch M is a researcher involved in the study of pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n590,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"VON MINCKWITZ G\"\"\",\"Here is a comprehensive summary of the data:\n\nSCHNEEWEISS A and VON MINCKWITZ G are co-authors of a research paper and a study on neoadjuvant carboplatin in early breast cancer.\n\nNote: I have concatenated the descriptions to provide a single, comprehensive summary, and resolved any potential contradictions to ensure a coherent output.\",17\r\n591,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"SCHMID P\"\"\",\"Here is a comprehensive summary of the data:\n\nSchmid P and Schneeweiss A are co-authors of multiple studies on breast cancer, specifically including a study on atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.\n\nNote: I resolved the contradiction by combining the two descriptions, ensuring that the summary includes all the relevant information and is written in third person.\",13\r\n585,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"CHIA S\"\"\",\"\"\"Schneeweiss A and Chia S are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n588,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"ENIU A\"\"\",\"\"\"Schneeweiss A and Eniu A are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n587,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"HARVEY V\"\"\",\"\"\"Schneeweiss A and Harvey V are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n582,\"\"\"HEGG R\"\"\",\"\"\"SCHNEEWEISS A\"\"\",\"\"\"Schneeweiss A and Hegg R are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n586,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"HICKISH T\"\"\",\"\"\"Schneeweiss A and Hickish T are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n589,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"WALDRON-LYNCH M\"\"\",\"\"\"Schneeweiss A and Waldron-Lynch M are co-authors of a study on pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.\"\"\",9\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": null}}